608 related articles for article (PubMed ID: 27135354)
1. Targeting the dopamine D3 receptor: an overview of drug design strategies.
Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of G protein-coupled receptor heteromers.
Moreno E; Casajuana-Martin N; Coyle M; Campos BC; Galaj E; Del Torrent CL; Seyedian A; Rea W; Cai NS; Bonifazi A; Florán B; Xi ZX; Guitart X; Casadó V; Newman AH; Bishop C; Pardo L; Ferré S
Pharmacol Res; 2022 Nov; 185():106476. PubMed ID: 36182040
[TBL] [Abstract][Full Text] [Related]
3. Current drug treatments targeting dopamine D3 receptor.
Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
[TBL] [Abstract][Full Text] [Related]
4. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
[TBL] [Abstract][Full Text] [Related]
5. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.
Kiss B; Laszlovszky I; Krámos B; Visegrády A; Bobok A; Lévay G; Lendvai B; Román V
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33466844
[TBL] [Abstract][Full Text] [Related]
6. Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.
Guitart X; Navarro G; Moreno E; Yano H; Cai NS; Sánchez-Soto M; Kumar-Barodia S; Naidu YT; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Ferré S
Mol Pharmacol; 2014 Oct; 86(4):417-29. PubMed ID: 25097189
[TBL] [Abstract][Full Text] [Related]
7. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
[TBL] [Abstract][Full Text] [Related]
8. Biased G Protein-Independent Signaling of Dopamine D
Guitart X; Moreno E; Rea W; Sánchez-Soto M; Cai NS; Quiroz C; Kumar V; Bourque L; Cortés A; Canela EI; Bishop C; Newman AH; Casadó V; Ferré S
Mol Neurobiol; 2019 Oct; 56(10):6756-6769. PubMed ID: 30919214
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor-Receptor Interaction and Striatal Function.
Bono F; Mutti V; Tomasoni Z; Sbrini G; Missale C; Fiorentini C
Curr Top Behav Neurosci; 2023; 60():47-72. PubMed ID: 35505059
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
Cao Y; Min C; Acharya S; Kim KM; Cheon SH
Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
[TBL] [Abstract][Full Text] [Related]
12. The D3 dopamine receptor: From structural interactions to function.
Fiorentini C; Savoia P; Bono F; Tallarico P; Missale C
Eur Neuropsychopharmacol; 2015 Sep; 25(9):1462-9. PubMed ID: 25532864
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
Solís O; Garcia-Montes JR; González-Granillo A; Xu M; Moratalla R
Cereb Cortex; 2017 Jan; 27(1):435-446. PubMed ID: 26483399
[TBL] [Abstract][Full Text] [Related]
14. Advances and challenges in the search for D
Moritz AE; Free RB; Sibley DR
Cell Signal; 2018 Jan; 41():75-81. PubMed ID: 28716664
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection.
Bono F; Mutti V; Fiorentini C; Missale C
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32659920
[TBL] [Abstract][Full Text] [Related]
16. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Keck TM; John WS; Czoty PW; Nader MA; Newman AH
J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH
Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029
[TBL] [Abstract][Full Text] [Related]
20. Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation.
Maggio R; Scarselli M; Capannolo M; Millan MJ
Eur Neuropsychopharmacol; 2015 Sep; 25(9):1470-9. PubMed ID: 25453482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
